Jeffrey Kagan, MD
Internal Medicine · Newington, CTNPI 1003886193
Payments from drug & device makers
Across 251 payments — averaging $56.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Astellas Pharma US Inc$2K
- AstraZeneca$1K
- AbbVie$1K
- BD$723
- Boehringer Ingelheim$518
- plus $5K from 35 others
What the payments were for
- Consulting fees$7235%
- Speaking & faculty fees$4,75434%
- Travel & lodging$300%
- Food & beverage$8,60761%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 20 | $3,735 |
| Astellas Pharma US Inc | 8 | $1,730 |
| AstraZeneca | 27 | $1,489 |
| AbbVie(2 entities) | 35 | $1,039 |
| BD | 2 | $723 |
| Boehringer Ingelheim | 10 | $518 |
| Amgen | 11 | $497 |
| Pfizer | 19 | $367 |
| Neurocrine Biosciences, Inc. | 4 | $355 |
| Axsome Therapeutics, Inc. | 3 | $353 |
| Novo Nordisk | 28 | $353 |
| Lilly USA, LLC | 10 | $345 |
| Eisai Inc. | 3 | $317 |
| Cepheid | 1 | $274 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $235 |
| Bayer | 2 | $234 |
| Scilex Pharmaceuticals Inc. | 9 | $181 |
| Abbott | 2 | $150 |
| GSK | 3 | $136 |
| Novartis | 8 | $130 |
| Gilead | 2 | $121 |
| Cardinal Health 200 LLC | 2 | $114 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $112 |
| Biocomposites Inc | 1 | $95 |
| E.r. Squibb & Sons, L.L.C. | 3 | $64 |
| Merck | 5 | $61 |
| Mylan Specialty L.p. | 2 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Avanir Pharmaceuticals, Inc. | 3 | $46 |
| Sanofi | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 2 | $25 |
| Amarin Pharma, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Alkermes, Inc. | 1 | $16 |
| Seqirus USA Inc | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Shionogi Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,126 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 523 | $178,788 |
| JardianceEmpagliflozin | 168 | $117,534 |
| JanuviaSitagliptin Phosphate | 62 | $72,588 |
| OzempicSemaglutide | 53 | $65,639 |
| FarxigaDapagliflozin Propanediol | 77 | $61,676 |
| TradjentaLinagliptin | 160 | $60,539 |
| XareltoRivaroxaban | 111 | $57,132 |
| MyrbetriqMirabegron | 101 | $38,740 |
| NuedextaDextromethorphan Hbr/Quinidine | 18 | $29,215 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $22,294 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $20,300 |
| Teriparatide | 12 | $19,208 |
| KerendiaFinerenone | 22 | $19,133 |
| Spiriva HandihalerTiotropium Bromide | 31 | $19,037 |
| RybelsusSemaglutide | 13 | $18,716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Stiolto Respimat | $518 | $196,404354 claims |
| PfizerEliquis | $367 | $178,788523 claims |
| MerckJanuvia, Janumet Xr | $61 | $94,88277 claims |
| Novo NordiskOzempic, Rybelsus | $353 | $84,35566 claims |
| AstraZenecaFarxiga | $1,489 | $61,67677 claims |
| Johnson & JohnsonXarelto | $3,735 | $57,132111 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $136 | $39,18575 claims |
| Astellas Pharma US IncMyrbetriq | $1,730 | $38,740101 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $46 | $29,21518 claims |
| AbbVieLinzess, Synthroid | $1,039 | $22,958127 claims |
| BayerKerendia | $234 | $19,13322 claims |
| Lilly USA, LLCMounjaro | $345 | $14,29613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Newington
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
- Margaret ChusteckaHamden$652K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.